Oncology

Featured coverage from the 70th Annual Roy A. Bowers Pharmaceutical Conference, held September 19, 2022. The theme for the 2022 conference was Innovation Through Crisis: Redefining Health Care Delivery.

Implications of Telehealth Use on the Future of Oncology Care

The concluding keynote address at the Academy of Managed Care Pharmacy Nexus 2022 meeting discussed new and emerging oncology drugs in the pipeline and their potential impact on the treatment landscape as it pertains to managed care providers.

The sessions align with the yearlong theme selected by this year’s ACCC president, David R. Penberthy, MD, MBA, when he took the helm in March: “Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.”

Despite the potential incentives for medical oncologists to reduce radiation therapy utilization under the Oncology Care Model, we find no evidence that such reduction occurred.

The targeted therapy, to be sold by Taiho Oncology as Lytgobi, had previously received breakthrough status in 2021 and was accepted for priority review in March.

HHS declared a public health emergency in Puerto Rico due to Hurricane Fiona; nearly 1 in 10 Americans suffered from depression in 2020, and a task force recommended doctors screen all adults aged younger than 65 for anxiety; advances in cancer research have led to reduced cancer death rates.

The rise of telehealth during COVID-19, its limitations, and its uncertain future.

A team of investigators from across the United States investigated a potential connection between patients’ health insurance literacy and their reported financial hardship.

Ravi B. Parikh, MD, MPP, assistant professor, Department of Medical Ethics and Health Policy and Medicine, Perelman School of Medicine, University of Pennsylvania, presented long-term results from an experiment with an algorithm designed to prompt oncologists to have serious illness conversations.

A survey was conducted to determine opportunities to aid primary care providers and patients in the difficult journey of an oncology patient.

At a panel for the National Health Alliance, 3 experts talked about incorporating patient needs and requests in cancer care.

Why "tech-enabled" solutions make sense and how the Music City became the a health care hub.

Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS) since August 2020, discusses the future of value-based care for the practice as the Oncology Care Model comes to an end.

Amy Valley, PharmD, vice president of clinical strategy and technology solutions, Cardinal Health Specialty Solutions, discusses the Decision Path, a clinical support tool designed to inform oncology providers about drug costs along with clinical information, all embedded into the electronic health record workflow.

Four experts from The US Oncology Network partnered with The American Journal of Managed Care® to present a webinar, “Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care?”

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

As part of its inquiry, the Federal Trade Commission (FTC) will demand that the 6 largest pharmacy benefit managers (PBMs) submit records and answer questions regarding their business practices.

The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.

The dysfunction with pharmacy benefit managers (PBMs) is so troublesome that the Federal Trade Commission (FTC) is currently investigating how they have driven up costs. Until May 25, the FTC is holding a public comment period on PBM practices.

Across commercial insurance, Medicare, and Medicaid populations, oncology is the top category of spend, and the drug pipeline has increasing specific and complex therapies.